消退素对肠易激综合征中TRPV1敏化及内脏高敏感的作用
该研究探讨消退素(RvD1、RvD2、RvE1)对TRPV1激活与敏化及内脏高敏感的作用。体外实验显示三种消退素均可预防组胺诱导的TRPV1敏化,RvD2还可逆转组胺及IBS上清液所致的敏化,该效应由GPR18介导。RvD2在两种临床前模型中使结直肠扩张的疼痛反应正常化,并减少IBS患者直肠黏膜下神经元的辣椒素诱导钙反应。
要点
- RvD1、RvD2和RvE1在无镇痛效应的剂量下预防组胺诱导的DRG神经元TRPV1敏化。
- RvD2逆转组胺及IBS上清液诱导的TRPV1敏化,该效应被GPR18拮抗剂O-1918(3-30 µM)及百日咳毒素阻断。
- RvD2使两种内脏高敏感临床前模型对结直肠扩张的疼痛反应正常化。
核心结论
- 数据提示RvD2及GPR18激动剂可能是有待进一步评估的IBS治疗新化合物。
研究设计与样本
- 采用小鼠背根神经节神经元活细胞钙成像评估RvD1、RvD2和RvE1对TRPV1激活与敏化的影响。
- 基于体外结果,在小鼠感染后IBS模型及大鼠炎症后内脏高敏感模型中进一步研究RvD2的体内效应。
- 最后在IBS患者直肠活检标本中测试RvD2对黏膜下神经元的作用。
主要发现
- RvD1、RvD2和RvE1在无镇痛效应的剂量下预防组胺诱导的DRG神经元TRPV1敏化。
- RvD2还逆转组胺及IBS上清液诱导的TRPV1敏化,该效应被GPR18拮抗剂O-1918(3-30 µM)及百日咳毒素阻断。
- RvD2减少IBS患者直肠黏膜下神经元对辣椒素诱导的Ca2+反应。
- RvD2治疗使两种内脏高敏感临床前模型对结直肠扩张的疼痛反应正常化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Resolvins (RvD1, RvD2 and RvE1) are endogenous anti-inflammatory lipid mediators that display potent analgesic properties in somatic pain by modulating transient receptor potential vanilloid 1 (TRPV1) activation. To what extent these molecules could also have a beneficial effect on TRPV1 sensitisation and visceral hypersensitivity (VHS), mechanisms involved in IBS, remains unknown. DESIGN: The effect of RvD1, RvD2 and RvE1 on TRPV1 activation and sensitisation by histamine or IBS supernatants was assessed on murine dorsal root ganglion (DRG) neurons using live Ca2+ imaging. Based on the results obtained in vitro, we further studied the effect of RvD2 in vivo using a murine model of post-infectious IBS and a rat model of post-inflammatory VHS. Finally, we also tested the effect of RvD2 on submucosal neurons in rectal biopsies of patients with IBS. RESULTS: RvD1, RvD2 and RvE1 prevented histamine-induced TRPV1 sensitisation in DRG neurons at doses devoid of an analgesic effect. Of note, RvD2 also reversed TRPV1 sensitisation by histamine and IBS supernatant. This effect was blocked by the G protein receptor 18 (GPR18) antagonist O-1918 (3-30 µM) and by pertussis toxin. In addition, RvD2 reduced the capsaicin-induced Ca2+ response of rectal submucosal neurons of patients with IBS. Finally, treatment with RvD2 normalised pain responses to colorectal distention in both preclinical models of VHS. CONCLUSIONS: Our data suggest that RvD2 and GPR18 agonists may represent interesting novel compounds to be further evaluated as treatment for IBS.
引用
- Perna E, Aguilera-Lizarraga J, Florens MV, et al. Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS. Gut. 2020. PMID: 33023902. doi:10.1136/gutjnl-2020-321530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。